Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer

By E. Miele, G. Spinelli, E. Miele, F. Tomao, S. Tomao. International Journal of Nanomedicine, 2009

775 citations recorded by the source corpus.

Breast cancer is the most common type of malignancy diagnosed in women. In the metastatic setting this disease is still uncurable. Taxanes represent an important class of antitumor agents which have proven to be fundamental in the treatment of advanced and early-stage breast cancer, but the clinical advances of taxanes have been limited by their highly hydrophobic molecular status. To overcome this poor water solubility, lipid-based solvents have been used as a vehicle, and new systemic formulations have been developed, mostly for paclitaxel, which are Cremophor-free and increase the circulation time of the drug. ABI-007 is a novel, albumin-bound, 130-nm particle formulation of paclitaxel, free from any kind of solvent. It has been demonstrated to be superior to an equitoxic dose of standard paclitaxel with a significantly lower incidence of toxicities in a large, international, randomized phase III trial. The availability of new drugs, such as Abraxane®, in association with other traditional and non-traditional drugs (new antineoplastic agents and targeted molecules), will give the oncologist many different effective treatment options for patients in this setting.

Subfields: Biomaterials, Oncology

View Paper: https://www.semanticscholar.org/paper/9c30849d7bf9959b23857ef99a57f45dc442e3a5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

In Oncology

Citations in the corpus

The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment (2020, background): “Several nanodrugs, such as Doxil [25] and Abraxane [26], have been approved by the FDA for clinical use.”
To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. (2010, background): “breast, lung and prostate), which could explain why albumin is known to accumulate in some tumors and thus facilitates intratumor accumulation of albumin-bound drugs [64,65].”
Cancer nanomedicine: a review of recent success in drug delivery (2017, background): “This effect may increase clearance from the bloodstream via recognition by the immune system or disrupt the ability of the nanoparticles to be internalized by the tissue of interest [26, 27].”
Progress of drug-loaded polymeric micelles into clinical studies. (2014, neutral): “lung and pancreatic cancer [26,27], paclitaxel-conjugated poly(glutamic acid) [28] (Opaxio) is being studied in Phase III for patients with advanced ovarian cancer (NCT00108745), and micelles from PEG-bpoly(D,L-lactide) copolymer incorporating Ptx in their hydrophobic core [29] (Genexol-PM) have bee”
Nanoparticles for Cancer Therapy: Current Progress and Challenges (2021, background): “Abraxane® alone or in combination with another cytotoxic agent such as gemcitabine diminish pancreatic stroma in pancreatic cancer xenograft mouse models [36].”
Nanoparticles in the clinic (2016, background): “The lone nonliposomal nanoparticle system currently approved for cancer treatments is Abraxane, which is an albumin-bound paclitaxel nanoparticle.(33) The majority of these formulations are not PEGylated, with the exception of Doxil and Onivyde,(34) which is perhaps surprising given the widely known”
Targeting Strategies for Multifunctional Nanoparticles in Cancer Imaging and Therapy (2012, background): “These agents circulate in the body with a half-life about 100 times longer than that of free anticancer drugs while simultaneously reducing systemic toxicity [17-21].”